C9orf72 motor neurons are among the most affected neuronal populations in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), representing the most common genetic cause of these neurodegenerative diseases. The hexanucleotide repeat expansion in the C9orf72 gene (GGGGCC repeat) is responsible for approximately 40% of familial ALS cases and 25% of familial FTD cases 1. This expansion leads to multiple pathological mechanisms including toxic RNA foci formation, dipeptide repeat (DPR) protein aggregation, and reduced C9orf72 protein expression, ultimately causing progressive motor neuron degeneration 2. [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Disease-Specific Neurons | [4]
| Location | Motor cortex (upper motor neurons), Spinal cord anterior horn (lower motor neurons) | [5]
| Cell Types | Corticospinal motor neurons, Spinal motor neurons | [6]
| Primary Neurotransmitter | Glutamate | [7]
| Key Markers | C9orf72, TDP-43, Poly-GA, Poly-GP, Poly-GR | [8]
| Associated Gene | C9orf72 (Chromosome 9) | [9]
| Disease Association | ALS, FTD, ALS-FTD spectrum | [10]
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000100 | motor neuron |
| Database | ID | Name | Confidence | [11]
|----------|----|------|------------| [12]
| Cell Ontology | CL:0000100 | motor neuron | Medium | [13]
The C9orf72 gene encodes a DENN domain protein involved in Rab GTPase regulation and autophagy 3: [14]
| Feature | Normal | Pathological | [15]
|---------|--------|--------------| [16]
| Repeat length | 2-8 | 60-1000+ | [17]
| Age of onset | N/A | 40-60 years | [18]
| Penetrance | N/A | Age-dependent | [19]
The expansion occurs in the first intron of C9orf72, creating multiple pathogenic mechanisms 4: [20]
The expanded repeat is transcribed bidirectionally, generating sense and antisense RNA that forms nuclear RNA foci 5: [21]
Five different DPRs are translated from the expansion (via repeat-associated non-ATG translation):
| DPR Type | Properties | Toxicity Mechanism |
|---|---|---|
| Poly-GA | Most abundant | Impairs proteasome, disrupts nucleocytoplasmic transport |
| Poly-GR | Arginine-rich | Binds RNA, disrupts nucleolar function |
| Poly-PR | Arginine-rich | Strongest toxicity, disrupts liquid-liquid phase separation |
| Poly-GP | Less abundant | Intermediate toxicity |
| Poly-GA | Forms inclusions | May sequester proteins |
The poly-GR and poly-PR DPRs are particularly toxic to neurons 6
The expansion leads to decreased C9orf72 expression through multiple mechanisms 7:
C9orf72 loss-of-function affects:
C9orf72-associated ALS presents with typical ALS features:
Additional features in C9orf72 carriers:
C9orf72 motor neurons show characteristic pathological features:
C9orf72 is the most common genetic cause of FTD:
C9orf72-FTD shows distinctive features:
ASOs represent the most promising disease-modifying approach:
Allele-unspecific ASOs: Target both wild-type and mutant C9orf72 9
Allele-specific ASOs: Target only mutant allele 10
DPR-targeting ASOs: Target translation of DPRs 11
RNA foci disaggregation: Small molecules to dissolve RNA foci 13
DPR aggregation inhibitors: Prevent DPR aggregation and toxicity 14
Autophagy enhancers: Compensate for C9orf72 loss-of-function 15
Nucleocytoplasmic transport modulators: Restore nuclear import/export 16
| Model Type | Advantages | Limitations |
|---|---|---|
| iPSC-derived motor neurons | Patient-specific, human | Variable differentiation |
| iN cells | Rapid conversion | Limited maturation |
| Motor neuron spheroids | 3D complexity | Variable reproducibility |
Key findings from cellular models 19:
The study of C9Orf72 Motor Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Renton AE, et al. A hexanucleotide repeat expansion in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257-268. 2011. ↩︎
DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245-256. 2011. ↩︎
Zhang D, et al. C9orf72 plays a central role in Rab-mediated autophagy. Nat Neurosci. 2012;15(5):648-653. 2012. ↩︎
Liu Y, et al. The C9orf72 expansion mutation: gene conversion, repeat composition, and founder effects. Brain. 2014;137(Pt 11):2960-2970. 2014. ↩︎
Gendron TF, et al. Antisense transcripts of the expanded C9orf72 repeat form RNA foci and sequester RNA-binding proteins. Acta Neuropathol. 2013;126(1):67-79. 2013. ↩︎
Mizielinska S, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila. Science. 2014;345(6201):1192-1194. 2014. ↩︎
van Blitterswijk M, et al. Association between C9orf72 repeat size and clinical phenotypes. JAMA Neurol. 2015;72(1):100-105. 2015. ↩︎
Mackenzie IR, et al. Pathological TDP-43 in sporadic ALS. Acta Neuropathol. 2013;126(1):59-72. 2013. ↩︎
Lagier-Tourenne C, et al. Targeted degradation of sense and antisense C9orf72 RNA foci. Proc Natl Acad Sci U S A. 2013;110(46):E4530-E4539. 2013. ↩︎
Jiang J, et al. Allele-specific silencing of mutant C9orf72 transcripts. Nat Commun. 2016;7:11745. 2016. ↩︎
ClinicalTrials.gov. WVE-004 for C9orf72-associated ALS/FTD. NCT04931862. ↩︎
Fusaki C, et al. RNA foci as therapeutic targets. Proc Natl Acad Sci U S A. 2014;111(41):E4336-E4345. 2014. ↩︎
Zhou Q, et al. DPR aggregation inhibitors for C9orf72 ALS. J Med Chem. 2020;63(21):12738-12755. 2020. ↩︎
Ugwu F, et al. Autophagy enhancers in C9orf72 ALS. Autophagy. 2019;15(9):1654-1656. 2019. ↩︎
Boeynaems S, et al. Nucleocytoplasmic transport disruption. Trends Cell Biol. 2021;31(1):41-54. 2021. ↩︎
Gendron TF, et al. Poly(GP) proteins in CSF as biomarkers. Acta Neuropathol. 2017;133(2):245-259. 2017. ↩︎
Blasco H, et al. Neurofilament light chain in C9orf72 carriers. Ann Neurol. 2020;87(4):544-552. 2020. ↩︎
Sareen D, et al. Modeling C9orf72 in iPSC-derived motor neurons. Cell Stem Cell. 2013;13(6):691-705. 2013. ↩︎
Liu Y, et al. C9orf72 BAC transgenic mice. Neuron. 2016;92(4):879-896. 2016. ↩︎
Xu W, et al. C9orf72 Drosophila model. Proc Natl Acad Sci U S A. 2013;110(46):E4436-E4444. 2013. ↩︎
Swaminathan A, et al. C9orf72 zebrafish model. J Neurosci. 2018;38(16):3982-3994. 2018. ↩︎